Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H13N3O |
Molecular Weight | 179.219 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NNC(=O)C1=CC=NC=C1
InChI
InChIKey=NYMGNSNKLVNMIA-UHFFFAOYSA-N
InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
Molecular Formula | C9H13N3O |
Molecular Weight | 179.219 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy. Iproniazid is no longer clinically prescribed and has been withdrawn due to incidences of hepatotoxicity.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21397 Gene ID: 4128.0 Gene Symbol: MAOA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21200377 |
|||
Target ID: P27338 Gene ID: 4129.0 Gene Symbol: MAOB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21200377 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Marsilid Approved UseDepression Launch Date1951 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. | 1985 Sep-Oct |
|
[Depression in the elderly. Medical treatment]. | 2001 Feb 24 |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Sample Use Guides
50 patients with depression who had been considered suitable for E.C.T. were given iproniazid in doses up to 450 mg/day for periods varying from two to forty weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7340462
MItochondrial fractions were isolated from bovine tissue homogenates of bovine brain and suspended in 0.1 M phosphate buffer (pH 7.4). Mitochondrial fractions were pre-incubated with 5-HT (1 mM), 2-phenylethylamine
(0.8 mM), tyramine (3.2 mM), dopamine (3 mM) or Hi (10
mM) at 37 deg-C for 30 - 45 minutes. Bovine mitochondrial were further incubated with increasing concentrations of Iproniazid (0.001 to 0.1 mM) which caused gradual inhibition of the deamination of 5-HT, tyramine, and dopamine. At 1 mM of Iproniazid, there was a marked increase in HDA, which was quite small in the mitochondria not treated with Iproniazid. Treatment of bovine brain mitochondria with 1 mM Iproniazid did not induce the appearance of HDA if the catalytic sites of the MAO-A were blocked by clorgyline. A selective inhibitor of the MAO-B deprenyl did not prevent the appearance of HDA after treatment with Iproniazid.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:12:21 GMT 2023
by
admin
on
Fri Dec 15 17:12:21 GMT 2023
|
Record UNII |
D892HFI3XA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06AF05
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
||
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
||
|
LIVERTOX |
514
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
||
|
WHO-ATC |
N06AF05
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1480
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
D892HFI3XA
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
DB04818
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
m6392
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
5981
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
19
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
100000083125
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
200-218-8
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
SUB08283MIG
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
3748
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
DTXSID5023168
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
D007490
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
C97714
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
IPRONIAZID
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL92401
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY | |||
|
54-92-2
Created by
admin on Fri Dec 15 17:12:21 GMT 2023 , Edited by admin on Fri Dec 15 17:12:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |